Work Here?
Overview
Alumis develops precision therapies for immune-mediated diseases. By using genetic and disease biology insights, it designs targeted treatments and selects the right targets, molecules, indications, patient groups, endpoints, and possible combinations to optimize outcomes. The company differentiates itself by aligning therapy development with genetic and immunologic understanding to match medicines to the patients who will benefit most. Its goal is to improve clinical outcomes by bringing precision therapies to market and pursuing partnerships or licensing to support development and commercialization.
About Alumis
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2021
People at Alumis
People at Alumis who can refer or advise you
Simplify's Take
What believers are saying
- Phase 3 psoriasis data showed 68% PASI 90 response by Week 24 with durable 61% at Week 52.
- NDA submission planned for second half 2026, with Phase 2b lupus data expected in Q3 2026.
- $569.5 million cash runway extends operations into Q4 2027, supporting full pipeline development.
What critics are saying
- FDA may deny NDA due to TYK2 class safety concerns like retinitis pigmentosa or cardiac events within 6-12 months.
- Market share loss to approved TYK2 inhibitors like deucravacitinib likely within 12-18 months despite strong efficacy.
- Merger integration failure with ACELYRIN could delay lupus data and trigger investor confidence loss within 6-9 months.
What makes Alumis unique
- Envudeucitinib delivers class-leading 24-hour TYK2 inhibition approaching injectable biologic efficacy in oral form.
- Alumis uses precision medicine to select optimal targets, molecules, and patients for immune-mediated diseases.
- Post-ACELYRIN merger portfolio includes late-stage psoriasis and lupus candidates with multiple upcoming catalysts.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1B
Above
Industry Average
Funded Over
5 Rounds
Benefits
Health Insurance
Unlimited Paid Time Off
Remote Work Options
Commuter Benefits
Phone/Internet Stipend
Gym Membership
Stock Options
Performance Bonus
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 4%2 year growth
↑ 4%SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of
Alumis is Hiring for 17 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Alumis
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2021
Alumis is Hiring for 17 Jobs on Simplify!
Find jobs on Simplify and start your career today